According to an Associated Press report, the FDA has accepted an application for a pill intended for treatment of kidney cancer.
Aveo Oncology said the Food and Drug Administration will complete a review of Tivopath by July 28, which is the standard 10 month review of a new drug. Aveo and its partner Astellas Pharma Inc. want to market Tivopath as a treatment for advanced kidney cancer.
Tivopath, or tivozanib, is a tablet meant to be taken once per day. The companies, Aveo and Astellas Pharma, are also studying the drug as a treatment for other cancers including breast and colon.